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INTRODUCTION:
Autoimmune encephalitides are a group of neurologic 
diseases that affect the limbic system in response to 
infectious or autoimmune triggers. Some of these 
diseases have an association with cancers, and may 
present as paraneoplastic syndromes1. Several 
autoimmune encephalitides are characterized by 
antibodies that target neuronal cell surface receptors or 
synaptic proteins2. Many of these tumors may be 
treated by steroids, intravenous immunoglobulins, 
plasma exchange, rituximab, or cyclophosphamide3. 
Because these diseases are potentially treatable, a 
high index of suspicion is required to prevent neurologic 
morbidity. One such autoimmune encephalitis is 
GABA-B encephalitis, which presents with symptoms of 
limbic encephalitis, such as seizures, cognitive decline, 
and behavioral problems. It may also present with 
ataxia or opsoclonus-myoclonus4. Although the exact 
cause of GABA-B encephalitis is unclear, it may be 
preceded by systemic or neurologic viral infections or 
have no obvious trigger5. This diagnosis should be 
particularly considered in middle-aged or older adults 
with new-onset seizures and multiple neurologic 




A 67 year old gentleman presented with increasing 
forgetfulness, difficulty recognizing familiar people, 
reduced verbal output, visuospatial dysfunction, visual 
hallucinations and sleepiness for one month. He had a 
history of diabetes, hypertension, Bell’s palsy, benign 
prostatic hyperplasia, presbycusis and hypothyroidism. 
He had been prescribed antipsychotics and 
antidepressants by a psychiatrist with some 
improvement in his behavior. However, his cognition 
had not improved. The neurologic examination was 
significant for orofacial dyskinesia and a mini-mental 
state examination score of 24, with impaired 
registration, recall, and attention and calculation. He 
had a normal EEG. His contrast enhanced MRI brain 
showed chronic microvascular changes and age related 
atrophy. His CSF analysis showed a normal white cell 
count (<5 cells/µL), normal glucose 64 mg/dL), raised 
proteins (83.2 mg/dL) and antibodies positive against 
GABA-B receptors (shown in Figure). All other 
laboratory and CSF markers were normal. There was no 
evidence of an underlying neoplasm on a CT chest with 
contrast. He was treated with pulsed 
methylprednisolone (1 gram/day) for 3 days followed by 
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oral prednisolone (1 mg/kg/day). His symptoms 
improved rapidly and he was started on azathioprine 
with gradual tapering of prednisolone. However, 
tapering of prednisolone led to relapse of symptoms so 
he is being managed on fortnightly methylprednisolone 
with azathioprine and a gradual tapering of the oral 
steroids. At the last follow-up, the patient’s neurologic 
and psychiatric symptoms had markedly improved. 
 
Patient 2:
A 34 year old lady presented with progressively 
worsening memory for recent events, repetition of 
speech, visual hallucinations, delusions, disinhibition, 
psychomotor agitation and urinary and fecal 
incontinence for a year. She did not have any past 
medical history of note. Her initial neurological 
examination and workup was normal. Her serum 
autoimmune antibody profile showed antibodies 
against GABA-B receptors (shown in Figure). It is 
important to note that anti-GABA-B antibodies should 
preferably  be checked in the CSF. However, this patient 
had refused CSF analysis. Therefore, the antibodies 
were checked in the serum. She was managed with 
methylprednisolone (1 gram/day) for 5 days followed by 
oral steroids. The patient did not improve so plasma 
exchange was done. She was advised rituximab for 
maintenance therapy, but her family declined further 
treatment due to financial reasons. Her follow-up 
evaluation revealed a static neurological condition.    
DISCUSSION:
The incidence of anti GABA-B antibody positivity in 
patients tested for autoimmune encephalitis related 
antibodies is around 0.2%7. We tested 640 samples 
(both sera and CSF) for autoimmune encephalitis 
associated antibodies from January 2015 to October 
2019 and 2 (0.3%) were positive for anti GABA-B 
antibodies.  According to the most recent published 
literature, the median age of patients presenting with 
anti GABABR encephalitis is 66 years with an almost 
equal incidence in males and females8. Similarly, in our 
patients, the mean age was 50.5 years with an equal 
gender distribution. However, this is a report of two 
patients only. Therefore, conclusions should be drawn 
with caution. The most common presenting symptom is 
seizures8, however, none of our patients had seizures 
during the disease course. Patient 1 presented with 
memory dysfunction and neuropsychiatric 
disturbances, whereas Patient 2 presented with 
behavioral problems. 
Around 50% of the patients with anti-GABA-B 
antibodies have an underlying small cell lung cancer9. 
However, both our patients were negative for 
malignancy after extensive workup. Anti-GABA-B 
encephalitis is also associated with presence of 
antibodies against other intracellular neuronal antigens 
like amphyphysin, Ri (ANNA2) and SOX-19. Patient 1 
had negative test result for an immunoblot panel of 
nine antibodies against intracellular neuronal antigens 
PNMA2, amphyphysin, CV2, Ri, Yo, Hu, Recoverin , 
SOX-1 and titin.
  
Around 60 to 70% of patients with anti-GABA-B 
encephalitis show complete or partial response to 
immunosuppressive therapy10. Patient 1 showed 
complete recovery with parenteral and oral steroids. 
However, Patient 2 did not improve with steroids and 
plasma exchange. Because of financial issues, Patient 
2 and her family refused further treatment. 
CONCLUSION
In conclusion, anti-GABA-B encephalitis represents a 
potentially treatable cause of cognitive decline and 
neuropsychiatric disturbances. A high index of 
suspicion should be kept for GABA-B and related 
encephalitides as they present with a diverse range of 
symptoms. 
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Figure.  Indirect  Immunofloresence using  U90 cells 
(Euroimmun, Leubeck Germany) transfected with 
genes of  GABAB receptors,  showing anti GABAB 
receptor antibodies. Non transfected cells were used 
as negative control.
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